AMGEN PRESENTS NEW PHASE 2 DATA THAT SHOW OLPASIRAN DELIVERS SIGNIFICANT REDUCTION IN LIPOPROTEIN(A) LEVELS

Olpasiran Reduced Lipoprotein(a) Levels by More Than 95% in Patients With Established ASCVD Amgen is Initiating a Phase 3 Cardiovascular Outcomes Trial Based on These Results Data Simultaneously Published in the New England Journal of Medicine THOUSAND OAKS, Calif. , Nov. 6, 2022...

Click to view original post